City of Hope has implemented policies and procedures to be in strict compliance with current ACCME Standards of Commercial Support requiring disclosure and resolution conflicts of interest.
As part of these new commercial guidelines, we are required to disclose if Faculty, Presenters, Authors, Planners, CME Committee Members, Course Directors and / or Moderators have any real or apparent vested commercial interest(s) in both those companies whose products may be discussed/described during the course of the activity and in those companies who may be acting as commercial supporters of the activity.
City of Hope further requires that prior to the activity Faculty have disclosed their intention to discuss any off label and/or investigational (not yet approved for any purpose) use of pharmaceutics or medical devices.
Dr. Lauhas indicated that he is a consultant for Intuitive Surgical and Covidien. Dr. Pal has indicated that he has received Grant/Research support from Amgen and on the Speaker's Bureau with Pfizer, Novartis and GSK and is a consultant with Novartis and Allos.
The following Planners and /orCMECommittee Members have indicated that they have nothing to disclose:
Teresa Ball, Kathleen Blazer, M.S.,Ed.D., Sandra Bolton, R.N.,J.D., Julianne Chun, Janet Crum, Ina Ervin, Jonathan Espenschied, Karl Gaal, M.D.,Jo Hanson, R.N., Fouad Kandeel, M.D., Patricia Kassab, R.N., M.S.,C.T.H.Q., Lucille Leong, M.D., Paul Lin, M.D., Matthew Loscalzo, M.S.W., Mary Mendelsohn, R.N.,M.S.N., Robert Morgan, Jr., M.D., Khanh Nguyen, M.D., Anna Pawlowska, M.D., I. Benjamin Paz, M.D., Lisa McDonald Reyes, B.S., Crystal Saavedra, B.S.and Jeffrey Weizel, M.D.
The following Planners and /or CMECommittee Members have declared they have the following relevant financial relationships to disclose:
Ravi Bhatia, M.D. - Consultant with Novartis& Bristol Myers Squibb, Martin Hogan, M.D. - Grant/Research Support from Johnson & Johnson, and Jean Kagan, B.A. - Stock Shareholder withAmgen/Zimmer.
Disclosure of Off-Label Use:
This activity may contain discussion of published and/or investigational uses of agents that are not approved/indicated by the US Food and Drug Administration (FDA). For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the official prescribing information for each product, or consult the Physicians’ Desk Reference. Participants from other r countries should consult with their respective regulatory authorities
Dr. Lau and Dr. Pal have indicated that they will not be discussing drugs that are off label or used for investigational purposes.This activity has been made possible in part by an unrestricted educational grant from Pfizer Inc.